Rate My Professor Justin Gooding

Scientia Professor Justin Gooding holds the position at the University of New South Wales (UNSW) in the Faculty of Science, School of Chemistry, where he serves as an ARC Industry Laureate Fellow. He earned a B.Sc. (Hons) from the University of Melbourne, followed by two years at ICI Research. He then obtained a D.Phil. from the University of Oxford and completed postdoctoral training at the Institute of Biotechnology, University of Cambridge. Returning to Australia in 1997 as a Vice-Chancellor’s Postdoctoral Research Fellow at UNSW, he held a lectureship at Flinders University in 1998 before joining UNSW in 1999. Promoted to full Professor in 2006 and to Scientia Professor—the university’s highest research accolade—in 2011, Gooding leads a research team of over 30 members focused on surface modification and nanotechnology for biosensors, biomaterials, electron transfer, and medical applications.

Gooding has authored over 550 research papers in leading journals including Nature Nanotechnology, Nature Biotechnology, Nature Photonics, Nature Immunology, Nature Communications, and Science Advances, alongside 19 patents and the textbook Data Analysis for Chemistry (Oxford University Press, 2006). His work has garnered more than 36,000 citations with a Scopus H-index of 95. A Fellow of the Australian Academy of Science, Australian Academy of Technology and Engineering, Australian Academy of Health and Medical Sciences, and International Society of Electrochemistry, he has received the David Craig Medal and Lecture (2024), three Australia Museum Eureka Prizes (Scientific Research 2009, Mentoring of Young Researchers 2017, Innovative Use of Technology 2021), Faraday Medal from the Royal Society of Chemistry, Katsumi Niki Prize in Bioelectrochemistry (2017), Jaroslav Heyrovsky Prize for Molecular Electrochemistry (2020), and multiple Elsevier Biosensors and Bioelectronics Awards. As inaugural Editor-in-Chief of ACS Sensors, he has shaped the field significantly. His innovations have contributed to commercial ventures, including AgaMatrix’s worldwide glucose biosensors, Inventia Life Sciences’ 3D bioprinters, and Nutromics’ wearable biosensors undergoing human trials.